ANTENGENE-B(06996): ATG-201 for the treatment of B cell-mediated autoimmune diseases has received HREC approval for the Phase I ATTRACT study in Australia.
Deqi Medical-B (06996) announced that the Board of Directors is pleased to declare that the Phase I ATTRACT study of ATG-201 (a CD19/CD3 bispecific T cell engager antibody developed by the group for the treatment of B cell-related autoimmune diseases) has obtained approval from the Human Research Ethics Committee (HREC) of Australia, and the process of submitting the Clinical Trial Notification (CTN) to the Therapeutic Goods Administration (TGA) has been completed.
ANTENGENE-B (06996) announced that the company's board of directors is pleased to report that the Phase I ATTRACT study for ATG-201, a CD19/CD3 bispecific T cell engager antibody developed independently by the group for the treatment of B cell-related autoimmune diseases, has received approval from the Human Research Ethics Committee (HREC) in Australia and has completed the process of submitting the Clinical Trial Notification (CTN) to the Therapeutic Goods Administration (TGA).
Related Articles
China Securities Co., Ltd.: The steady promotion of the storage IPO is favorable for semiconductor equipment, and the shipbuilding industry continues to experience an upward trend in prosperity.
TUYA-W (02391) released its interim results, with a net profit of 34.40 million USD, an increase of 45.8% year-on-year.
New Stock News | Yixin Communications has once again submitted an application to the Hong Kong Stock Exchange, ranking third in the global cellular communication chip market.
China Securities Co., Ltd.: The steady promotion of the storage IPO is favorable for semiconductor equipment, and the shipbuilding industry continues to experience an upward trend in prosperity.
TUYA-W (02391) released its interim results, with a net profit of 34.40 million USD, an increase of 45.8% year-on-year.
New Stock News | Yixin Communications has once again submitted an application to the Hong Kong Stock Exchange, ranking third in the global cellular communication chip market.
RECOMMEND
